Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in...
-
More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1New data from UZEDY®...
-
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on...
-
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial...
-
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two...
-
SANTA BARBARA, Calif. and PARSIPPANY, N.J. , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Direct Relief, Teva Pharmaceuticals, and the National Association of Free and Charitable Clinics (NAFC) today announced...
-
UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults1LAI treatment options may help address...
-
New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on...
-
AMSTERDAM, 21 févr. 2025 (GLOBE NEWSWIRE) -- Une nouvelle étude de Teva Pharmaceuticals Europe révèle que 46 % des médicaments génériques figurant sur la liste des médicaments essentiels de...
-
AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der kritischen Arzneimittel von nur einem Anbieter...